JHcispoly news| Initiation meeting of a prospective multicenter cohort study of DNA methylation in gynecologic cancer screening.
Led by Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, the kick-off meeting of "prospective multicenter cohort study of DNA methylation for cervical lesions screening" was held in Beijing Hilton Hotel in the afternoon of March 6.This multicenter study is the first multicenter prospective study on gene DNA methylation in gynecological tumors in China.
Participating hospitals included Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Third Hospital of Peking University, International Hospital of Peking University, Cancer Hospital of Peking University, sixth and seventh medical centers of General Hospital of Chinese people's Liberation Army, Cangzhou Central Hospital of Hebei Province and people's Hospital of Inner Mongolia Autonomous Region.
Professor Li Lei from Peking Union Medical College Hospital of Chinese Academy of Medical Sciences briefly introduced the preliminary research and multi center program, and elaborated the application value of DNA methylation as an independent early screening index in gynecological malignancies.
Professor Li Lei introduces the project
Target: 20000 cases (12000 cases included)
Enrolled population: cervical cancer screening population based on outpatient service
Dr. Wang Linhai, CTO of Juhe biology, introduced the preliminary research results with Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Phase I retrospective study data report (published, impact factor 5.1)
Data report of phase II prospective study (completed)
Report on progress of multi center prospective work in phase III
The participating teachers communicated with each other on the details of the multi center work, such as the consistency of Cin2 biopsy and postoperative pathology, colposcopy tracking of enrolled patients, and multi center in-depth study of cervical adenocarcinoma with negative TCT and HPV.
In addition, the progress of early screening and early diagnosis of ovarian cancer and endometrial cancer was also discussed and data were presented.